Chemical Reviews pubs.acs.

org/CR Review

Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance in EGFR-Mutant NSCLC and Clinical Validation of Combined
Mutations that Spares the Wild Type Form of the Receptor. J. Med. EGFR and RET Inhibition with Osimertinib and BLU-667 for
Chem. 2014, 57, 8249−8267. Acquired RET Fusion. Cancer Discovery 2018, 8, 1529−1539.
(238) Cross, D. A.; Ashton, S. E.; Ghiorghiu, S.; Eberlein, C.; (252) Grugan, K. D.; Dorn, K.; Jarantow, S. W.; Bushey, B. S.;
Nebhan, C. A.; Spitzler, P. J.; Orme, J. P.; Finlay, M. R.; Ward, R. A.; Pardinas, J. R.; Laquerre, S.; Moores, S. L.; Chiu, M. L. Fc-Mediated
Mellor, M. J.; et al. AZD9291, an Irreversible EGFR TKI, Overcomes Activity of EGFR x c-Met Bispecific Antibody JNJ-61186372
T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer. Enhanced Killing of Lung Cancer Cells. MAbs 2017, 9, 114−126.
Cancer Discovery 2014, 4, 1046−1061. (253) Baraibar, I.; Mezquita, L.; Gil-Bazo, I.; Planchard, D. Novel
(239) Soria, J.-C.; Ohe, Y.; Vansteenkiste, J.; Reungwetwattana, T.; Drugs Targeting EGFR and HER2 Exon 20 Mutations in Metastatic
Chewaskulyong, B.; Lee, H. H.; Dechaphunkul, A.; Imamura, F.; NSCLC. Crit. Rev. Oncol. Hematol. 2020, 148, 102906.
Nogami, N.; Kurata, T.; et al. Osimertinib in Untreated EGFR- (254) Grabe, T.; Lategahn, J.; Rauh, D. C797S Resistance: The
Mutated Advanced Non-Small-Cell Lung Cancer. N. Engl. J. Med. Undruggable EGFR Mutation in Non-Small Cell Lung Cancer? ACS
2018, 378, 113−125. Med. Chem. Lett. 2018, 9, 779−782.
(240) Passaro, A.; Guerini-Rocco, E.; Pochesci, A.; Vacirca, D.; (255) Hanan, E. J.; Eigenbrot, C.; Bryan, M. C.; Burdick, D. J.;
Spitaleri, G.; Catania, C. M.; Rappa, A.; Barberis, M.; de Marinis, F. Chan, B. K.; Chen, Y.; Dotson, J.; Heald, R. A.; Jackson, P. S.; La, H.;
Targeting EGFR T790M Mutation in NSCLC: From Biology to et al. Discovery of Selective and Noncovalent Diaminopyrimidine-
Evaluation and Treatment. Pharmacol. Res. 2017, 117, 406−415. Based Inhibitors of Epidermal Growth Factor Receptor Containing
(241) Lelais, G.; Epple, R.; Marsilje, T. H.; Long, Y. O.; McNeill, the T790M Resistance Mutation. J. Med. Chem. 2014, 57, 10176−
M.; Chen, B.; Lu, W.; Anumolu, J.; Badiger, S.; Bursulaya, B.; et al. 10191.
Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2- (256) Chan, B. K.; Hanan, E. J.; Bowman, K. K.; Bryan, M. C.;
enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotina- Burdick, D.; Chan, E.; Chen, Y.; Clausen, S.; Dela Vega, T.; Dotson,
mide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor J.; et al. Discovery of a Noncovalent, Mutant-Selective Epidermal
of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Growth Factor Receptor Inhibitor. J. Med. Chem. 2016, 59, 9080−
Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung 9093.
Cancers. J. Med. Chem. 2016, 59, 6671−6689. (257) Uchibori, K.; Sato, S.; Fujita, N.; Katayama, R.; Inase, N.;
(242) Wang, S.; Cang, S.; Liu, D. Third-Generation Inhibitors Araki, M.; Okuno, Y.; Kamada, M. Brigatinib Combined with Anti-
Targeting EGFR T790M Mutation in Advanced Non-Small Cell Lung EGFR Antibody Overcomes Osimertinib Resistance in EGFR-
Cancer. J. Hematol. Oncol. 2016, 9, 34. Mutated Non-Small-Cell Lung Cancer. Nat. Commun. 2017, 8, 14768.
(243) Yun, J.; Hong, M. H.; Kim, S. Y.; Park, C. W.; Kim, S.; Yun, (258) Zhao, J.; Zou, M.; Lv, J.; Han, Y.; Wang, G.; Wang, G.
M. R.; Kang, H. N.; Pyo, K. H.; Lee, S. S.; Koh, J. S.; et al. YH25448, Effective Treatment of Pulmonary Adenocarcinoma Harboring Triple
an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR EGFR Mutations of L858R, T790M, and Cis-C797S by Osimertinib,
Mutant Non-Small Cell Lung Cancer. Clin. Cancer Res. 2019, 25, Bevacizumab, and Brigatinib Combination Therapy: A Case Report.
2575−2587. OncoTargets Ther. 2018, 11, 5545−5550.
(244) Xu, X.; Mao, L.; Xu, W.; Tang, W.; Zhang, X.; Xi, B.; Xu, R.; (259) Liu, X.; Zhang, X.; Yang, L.; Tian, X.; Dong, T.; Ding, C. Z.;
Fang, X.; Liu, J.; Fang, C.; et al. AC0010, an Irreversible EGFR Hu, L.; Wu, L.; Zhao, L.; Mao, J.; et al. Preclinical Evaluation of
Inhibitor Selectively Targeting Mutated EGFR and Overcoming TQB3804, a Potent EGFR C797S Inhibitor. Cancer Res. 2019, 79,
T790M-Induced Resistance in Animal Models and Lung Cancer 1320.
Patients. Mol. Cancer Ther. 2016, 15, 2586−2597. (260) Tucker, N. FDA Clears FDA IND For BBT-176 in Patients with
(245) Thress, K. S.; Stetson, D.; Dougherty, B.; Lai, Z.; Markovets, EGFR-Mutant NSCLC. Targeted Oncology. January 20, 2020.
A.; Barrett, J. C.; Paweletz, C. P.; Kuang, Y.; Janne, P. A.; Felip, E.; https://www.targetedonc.com/news/fda-clears-ind-for-bbt176-in-
et al. Acquired EGFR C797S Mutation Mediates Resistance to patients-with-egfrmutant-nsclc (accessed 2020-03).
AZD9291 in Non-Small Cell Lung Cancer Harboring EGFR T790M. (261) To, C.; Jang, J.; Chen, T.; Park, E.; Mushajiang, M.; De
Nat. Med. 2015, 21, 560−562. Clercq, D. J. H.; Xu, M.; Wang, S.; Cameron, M. D.; Heppner, D. E.;
(246) Chen, L.; Fu, W.; Zheng, L.; Liu, Z.; Liang, G. Recent et al. Single and Dual Targeting of Mutant EGFR with an Allosteric
Progress of Small-Molecule Epidermal Growth Factor Receptor Inhibitor. Cancer Discovery 2019, 9, 926−943.
(EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung (262) Wilson, L. J.; Linley, A.; Hammond, D. E.; Hood, F. E.;
Cancer. J. Med. Chem. 2018, 61, 4290−4300. Coulson, J. M.; MacEwan, D. J.; Ross, S. J.; Slupsky, J. R.; Smith, P.
(247) Arulananda, S.; Do, H.; Musafer, A.; Mitchell, P.; Dobrovic, D.; Eyers, P. A.; et al. New Perspectives, Opportunities, and
A.; John, T. Combination Osimertinib and Gefitinib in C797S and Challenges in Exploring the Human Protein Kinome. Cancer Res.
T790M EGFR-Mutated Non-Small Cell Lung Cancer. J. Thorac. 2018, 78, 15−29.
Oncol. 2017, 12, 1728−1732. (263) Engelhardt, H.; Bose, D.; Petronczki, M.; Scharn, D.; Bader,
(248) Liu, Y.; Li, Y.; Ou, Q.; Wu, X.; Wang, X.; Shao, Y. W.; Ying, J. G.; Baum, A.; Bergner, A.; Chong, E.; Dobel, S.; Egger, G.; et al. Start
Acquired EGFR L718V Mutation Mediates Resistance to Osimertinib Selective and Rigidify: The Discovery Path toward a Next Generation
in Non-Small Cell Lung Cancer But Retains Sensitivity to Afatinib. of EGFR Tyrosine Kinase Inhibitors. J. Med. Chem. 2019, 62, 10272−
Lung Cancer 2018, 118, 1−5. 10293.
(249) Oh, D. K.; Ji, W. J.; Kim, W. S.; Choi, C. M.; Yoon, S. K.; Rho, (264) An, S.; Fu, L. Small-Molecule PROTACs: An Emerging and
J. K.; Lee, J. C. Efficacy, Safety, and Resistance Profile of Osimertinib Promising Approach for the Development of Targeted Therapy
in T790M Mutation-Positive Non-Small Cell Lung Cancer in Real- Drugs. EBioMedicine 2018, 36, 553−562.
World Practice. PLoS One 2019, 14, e0210225. (265) Burslem, G. M.; Smith, B. E.; Lai, A. C.; Jaime-Figueroa, S.;
(250) Rangachari, D.; To, C.; Shpilsky, J. E.; VanderLaan, P. A.; McQuaid, D. C.; Bondeson, D. P.; Toure, M.; Dong, H.; Qian, Y.;
Kobayashi, S. S.; Mushajiang, M.; Lau, C. J.; Paweletz, C. P.; Oxnard, Wang, J.; et al. The Advantages of Targeted Protein Degradation Over
G. R.; Janne, P. A.; et al. Brief Report: EGFR-Mutated Lung Cancers Inhibition: An RTK Case Study. Cell Chem. Biol. 2018, 25, 67−77.
Resistant to Osimertinib Through EGFR-C797S Respond to 1(st) (266) Jaeschke, G.; Kuhn, B.; Ricci, A.; Rueher, D.; Steiner, S.;
Generation Reversible EGFR Inhibitors but Eventually Acquire Nagel, Y. A.; Duplessis, M.; Lazarski, K.; Liang, Y. Bifunctional
EGFR-T790M/C797S in Preclinical Models and Clinical Samples. J. inhibitors with egfr having a e3 ubiquitin ligase moiety.
Thorac. Oncol. 2019, 14, 1995−2002. WO2019121562A1, 2018.
(251) Piotrowska, Z.; Isozaki, H.; Lennerz, J. K.; Gainor, J. F.; (267) Gray, N.; Jang, J.; De Clercq, D.; Eck, M. Bifunctional
Lennes, I. T.; Zhu, V. W.; Marcoux, N.; Banwait, M. K.; Digumarthy, molecules for degradation of egfr and methods of use.
S. R.; Su, W.; et al. Landscape of Acquired Resistance to Osimertinib WO2017185036A1, 2017.

AY https://dx.doi.org/10.1021/acs.chemrev.0c00383
Chem. Rev. XXXX, XXX, XXX−XXX